Idarubicin (IDR) and high dose ARA C (HDARA C) in the treatment of relapsed/refractory acute nonlymphoid leukemia (ANLL), acute lymphocytic leukemia (ALL) and chronic myelogenous leukemia blast crisis (CML BC)
In the event we receive supplemental information to establish that the technology meets the cost criterion, and we were to approve new technology add-on payments for the NUsurface Meniscus Implant in the final rule, the maximum new technology add-on payment for a case involving the use of the NUsurface Meniscus Implant would be $6,366.75 ($9,795 0.65) for FY 2024 (that is, 65 ( percent of the average cost of the NUsurface Meniscus Implant)
where the product(s) of this reaction are denoted as Compound II
Pharmaceutics 20 , 545560 (2023)
Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by candida auris: results from a phase 2 trial
This supplement can cause serious side effects